Background: To maintain glucose control in T1DM is especially difficult in children that have unpredictable amounts of physical activity and broad eating patterns. Advances in diabetes technology include Continuous Subcutaneous Insulin Infusion (CSII) and patch/tubeless micropumps are newer options available. Patch pumps are free of tubing, small and lightweight. We aimed to report the initial clinical effect of an insulin micropump therapy in a cohort of children with T1DM.
Method: We studied pediatric patients (5-years old) , converting from multiple daily injections of insulin (MDI) to Roche Accu-chek Solo tubeless micropump system. Nine children (5 female/4 male) were followed during 1 and 3 months. All patients used Continuous Glucose Monitoring (CGM) and data was collected to learn time spent in hypoglycemia, normoglycemia and hyperglycemia, as well the glucose variability.
Results: Data from this small cohort showed that basal insulin infusion rates at baseline and 3 months were similar (7.7U to 7.6U) and insulin bolus requirements reduced from 14.3U to 12.7U, respectively. Based on CGM analysis the table below shows the % of time spent at different glycemia values (mean/SD) , as well its variability. HbA1c was 7.3% at baseline and 7.4% after 3 months, and there were no emergency room admissions due to severe hypoglycemia.
Conclusion: The initial results of this new insulin micropump therapy in children showed an improvement on glucose control and variability, without increasing hypoglycemia. Additional studies are necessary to demonstrate the medium and long-term effect of this new device in this population.
L. Rista: Advisory Panel; Roche Diabetes Care. Speaker's Bureau; AstraZeneca, Novo Nordisk. A. Flores: Speaker's Bureau; Novo Nordisk, Roche Diabetes Care, Sanofi. M. Rivers: Employee; Roche Diabetes Care. C. Vulcano: Employee; Roche Diabetes Care. E. Repetto: Employee; Roche Diabetes Care.